CER Daily Newsfeed

Video: Integrating Novel Lipid-Lowering Therapies and Addressing Cardiovascular Care Costs

(5/21, Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP, Joseph J. Saseen, PharmD, BCPS, BCACP, CLS, Tomasz Jurga, PharmD, BCPS, BCACP, Pharmacy Times) “...The experts examined enlicitide, an oral PCSK9 inhibitor currently under investigation, which could offer a convenient alternative to injectable therapies and may be incorporated into treatment algorithms for patients who are statin-intolerant or require additional LDL-C lowering. Its oral formulation may improve adherence compared with injectable PCSK9 inhibitors, though real-world data will be needed to confirm this.” View Video

Q&A: How RWE Is Reshaping Specialty Pharma Market Access

(5/21, Tommy Bramley, Stephen Appezzato, Pharmaceutical Commerce) reports “...Tommy Bramley, senior vice president of global consulting services at Cencora, has spent more than two decades working at this intersection of evidence generation, market access, and patient outcomes — and he has watched RWE evolve from a post-approval surveillance tool into an expected component of the evidence package that payers, providers, and regulators rely on throughout a therapy's life cycle...Bramley sat down with Pharmaceutical Commerce to discuss how evolving evidence expectations are reshaping reimbursement strategy, why specialty drugs require a distinct RWE approach, and how early evidence planning can accelerate patient access and strengthen collaboration across manufacturers, payers, and specialty pharmacy.” Full

ISPOR 2026 Daily Round-Ups: Insights from Day 3

(5/21, Joanne Walker, Katie McCool, Laura Dormer, The Evidence Base) reports “...Providing the science update, Eberechukwu Onukwugha (ISPOR Past President) outlined a productive year for ISPOR’s scientific activities, including updated HEOR competency frameworks, four Good Practice Reports in progress for publication, and continued work on frontier topics such as AI, RWE, value-based healthcare, patient centricity and whole health...Kelly Saldana (ISPOR Institute for Healthcare Transformation) described the Institute’s role as a bridge between evidence generation and implementation, helping ensure robust HEOR science translates more effectively into healthcare decisions and real-world practice globally.” Full

National Studies Show How the PCORnet® Infrastructure Supports Meaningful Engagement

(5/20, PCORnet Blog) comments “...‘Building a truly patient-centered research team in which patient partners were included at every step enabled us to create a study that drew people in,’ said Ruth Phillippi, MS, patient co-investigator and program lead at the Washington Adult Congenital Heart Program. ‘Not just to the registry but to a distinct and engaged research coalition that values our opinions and lived experiences.’ The CHI-RON study team also used the PCORnet® Common Data Model to help increase diversity in the trial.” Full

Senate Democrats Introduce CRA To Block WISeR Model

(5/20, Jalen Brown, Inside Health Policy) reports “...In a statement Wednesday, Senate Finance Committee ranking Democrat Ron Wyden (OR) framed the effort as forcing Republicans to take a public vote on the WISeR model, which they’re hoping could potentially have midterm election implications. ‘Americans are sick and tired of abusive prior authorization tactics putting needed health care out of reach. The last thing seniors need is even more AI denying the care they need,’ Wyden said. ‘Forcing a vote on this ill-conceived experiment will show the American people that Democrats are on the side of seniors and families who want timely access to health care, while Republicans want to import the worst abuses by insurance companies that Americans loathe into Traditional Medicare.’” Subscription Required

Health Canada Consults On Focused Approach To Implementing Drug Review Reliance

(5/21, Vibha Sharma, Pink Sheet) reports “...Health Canada is seeking feedback on the phased approach it wants to use to implement its regulatory reliance framework, which is aimed at improving patient access to drugs by relying on decisions or documents from trusted foreign regulators.” Subscription Required